Literature DB >> 8726153

Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study.

L T Rodwell1, S D Anderson.   

Abstract

Hyperosmolar aerosols are used to assess airway responsiveness in subjects with asthma. Using a 10% NaCl aerosol, we investigated airway responsiveness in 23 cystic fibrosis (CF) subjects (12 females, 11 males; 19.1 +/- 3.3 years) who had asthma-like symptoms. The pre-challenge predicted forced expiratory volume in 1 second (FEV1) was 74.7 +/- 21.5. The aerosol was generated by a MistO2gen 143A ultrasonic nebulizer and inhaled for 0.5, 1, 2, 4, 8, 8, and 8 minutes or part thereof. Spirometry was performed before and 1 minute after each inhalation period. The challenge was stopped when a > or = 20% fall from the baseline FEV1 was recorded, after the last inhalation period, or when requested by the subject. We recorded different responses to 10% NaCl among subjects. In 7, the FEV1 fell progressively throughout the challenge in a manner similar to asthmatics. By contrast, in 15 subjects the FEV1 was higher at the completion of challenge compared to during challenge, i.e., the fall in FEV1 was transient. In 7 of these subjects, the final FEV1 at the end of the challenge was higher than the pre-challenge FEV1. We conclude that inhaled 10% hyperosmolar saline causes either progressive and sustained or transient airway narrowing during challenge in the majority of CF subjects. The cause of the transient airway narrowing requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726153     DOI: 10.1002/(SICI)1099-0496(199605)21:5<282::AID-PPUL3>3.0.CO;2-P

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

1.  Bronchoprovocation testing.

Authors:  Chakravarthy Reddy
Journal:  Clin Rev Allergy Immunol       Date:  2009-03-17       Impact factor: 8.667

2.  Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis.

Authors:  M Robinson; A L Hemming; J A Regnis; A G Wong; D L Bailey; G J Bautovich; M King; P T Bye
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

3.  Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients.

Authors:  Maria Talamo Guevara; Susanna A McColley; Karen Rychlik; Adrienne P Savant
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-06       Impact factor: 0.885

4.  A modified nebulization modality versus classical ultrasonic nebulization and oxygen-driven nebulization in facilitating airway clearance in patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Qiaoling Luo; Zeguang Zheng; Huihong Cen; Mei Jiang; Qin Chen
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 5.  Global impact of bronchiectasis and cystic fibrosis.

Authors:  Margarida Redondo; Holly Keyt; Raja Dhar; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2016-09

Review 6.  Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review.

Authors:  Luis Máiz Carro; Miguel A Martínez-García
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 7.  Use of Hyaluronic Acid (HA) in Chronic Airway Diseases.

Authors:  Luis Máiz Carro; Miguel A Martínez-García
Journal:  Cells       Date:  2020-09-29       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.